Plasma protein C inhibitor is elevated in survivors of myocardial infarction

被引:31
作者
Carroll, VA
Griffiths, MR
Geiger, M
Merlo, C
Furlan, M
Lammle, B
Binder, BR
机构
[1] UNIV VIENNA,DEPT VASC BIOL & THROMBOSIS RES,TECHNOCLONE INC,A-1090 VIENNA,AUSTRIA
[2] UNIV HOSP BERN,INSELSPITAL,CENT HEMATOL LAB,CH-3010 BERN,SWITZERLAND
关键词
myocardial infarction; protein C inhibitor; plasminogen activator inhibitor-1; tissue plasminogen activator;
D O I
10.1161/01.ATV.17.1.114
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many studies have shown alterations of the hemostatic and fibrinolytic systems in patients with atherosclerotic disease, principally in levels of plasminogen activator inhibitor-1. However, in a large prospective study only fibrinogen, von Willebrand factor antigen, and tissue plasminogen activator antigen were found to be independent risk markers for acute coronary events. The present study evaluated the fibrinolytic system in coronary artery disease, paying particular attention to another inhibitor of fibrinolysis, plasminogen activator inhibitor-3, also called protein C inhibitor (PCI). One hundred fifteen nonanticoagulated male survivors of myocardial infarction were investigated for a range of hemostatic and fibrinolytic parameters that were compared with values in 87 age-matched healthy control male subjects. PCI active antigen was significantly (P<.03) elevated in the myocardial infarction group compared with the control group and was associated with the number of acute coronary events suffered (P=.005) but not with the severity of disease as determined by coronary angiography. Elevated PCI plasma levels can be considered as a risk marker for acute coronary events and might be of particular importance in the pathogenesis of this disease due to the interference of PCI in both the anticoagulant and fibrinolytic systems.
引用
收藏
页码:114 / 118
页数:5
相关论文
共 28 条
[1]   DIURNAL-VARIATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ITS RAPID INHIBITOR (PAI-1) [J].
ANGLETON, P ;
CHANDLER, WL ;
SCHMER, G .
CIRCULATION, 1989, 79 (01) :101-106
[2]  
Carroll V., 1995, Blood, V86, p379A
[3]  
CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
[4]   FIBRINOGEN LEVEL AS A PREDICTOR OF MORTALITY IN SURVIVORS OF MYOCARDIAL-INFARCTION [J].
COOPER, J ;
DOUGLAS, AS .
FIBRINOLYSIS, 1991, 5 (02) :105-108
[5]   INCREASED FIBRIN TURNOVER AND HIGH PAI-1 ACTIVITY AS PREDICTORS OF ISCHEMIC EVENTS IN ATHEROSCLEROTIC PATIENTS - A CASE-CONTROL STUDY [J].
CORTELLARO, M ;
COFRANCESCO, E ;
BOSCHETTI, C ;
MUSSONI, L ;
DONATI, MB ;
CARDILLO, M ;
CATALANO, M ;
GABRIELLI, L ;
LOMBARDI, B ;
SPECCHIA, G ;
TAVAZZI, L ;
TREMOLI, E ;
POZZOLI, E ;
TURRI, M ;
CORTELLARO, M ;
COFRANCESCO, E ;
BOSCHETTI, C ;
CARDILLO, M ;
TORRI, M ;
RAINISIO, M ;
GENTILE, G ;
MOREO, G ;
BIANCHI, O ;
LEONARDI, P ;
COLOMBI, M ;
CATALANO, M ;
GALIMBERTI, P ;
RUSSO, U ;
CRESSOTTI, A ;
CARZANIGA, G ;
NOBILI, S ;
NINNO, D ;
DONATI, MB ;
IACOVIELLO, L ;
DEGAETANO, G ;
GABRIELLI, L ;
MARTELLI, E ;
CORSI, G ;
LORENZI, G ;
LOMBARDI, B ;
CARRIERO, MR ;
COLOMBO, R ;
SPECCHIA, G ;
CIOFFI, P ;
SCIRE, A ;
TAVAZZI, L ;
GIANNUZZI, P ;
CORRA, U ;
TEMPORELLI, L ;
MORA, F .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (10) :1412-1417
[6]   DETERMINATION OF PLASMA PROTEIN-C INHIBITOR AND OF 2 ACTIVATED PROTEIN-C-INHIBITOR COMPLEXES IN NORMALS AND IN PATIENTS WITH INTRAVASCULAR COAGULATION AND THROMBOTIC DISEASE [J].
ESPANA, F ;
VICENTE, V ;
TABERNERO, D ;
SCHARRER, I ;
GRIFFIN, JH .
THROMBOSIS RESEARCH, 1990, 59 (03) :593-608
[7]   MECHANISMS OF DISEASE - THE PATHOGENESIS OF CORONARY-ARTERY DISEASE AND THE ACUTE CORONARY SYNDROMES .1. [J].
FUSTER, V ;
BADIMON, L ;
BADIMON, JJ ;
CHESEBRO, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (04) :242-250
[8]  
FUSTER V, 1992, NEW ENGL J MED, V326, P310
[9]  
GEIGER M, 1989, BLOOD, V74, P722
[10]  
GRAM J, 1995, THROMB HAEMOSTASIS, V74, P718